Research Study

A Phase III Clinical Trial of Intra-arterial TheraSphere® in the Treatment of Patients With Unresectable Hepatocellular Carcinoma (HCC)
Principal Investigator 
David Ming-Teh Liu

Overview

Body Locations and Systems 
Liver
Disorders and Conditions 
Liver Cancer
ClinicalTrials.gov# 
NCT01556490
Status 
Recruiting
Study Start/End 
Oct 8, 2014 to Aug 8, 2020
Locations 
Diamond Health Care Centre, Vancouver General Hospital
Name/Title 
Joanne Ford, Study Coordinator
Phone 
604-875-5705
Email Address 
joann.ford@vch.ca
Purpose of Study 

The safety and effectiveness of TheraSphere will be evaluated in patients with unresectable hepatocellular carcinoma in whom treatment with standard-of-care sorafenib is planned. All patients receive the standard-of-care sorafenib with or without the addition of TheraSphere.


 

Eligibility 

Visit ClinicalTrials.gov for more information. 

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.